Therefore, above experimental results indicate that targeting the HDAC7/β-catenin/c-Myc axis and USP10/HDAC7 pathway, and combining it with melatonin may be a novel strategy for anti-ESCC therapy. This evidence concerns the gene USP10 and esophageal squamous cell carcinoma.